HOME > NATION > Article

Text Size

small

medium

large


Shionogi Applies for Approval of Its COVID-19 Vaccine

Shionogi Applies for Approval of Its COVID-19 Vaccine

   Osaka, Nov. 24 (Jiji Press)--Shionogi & Co. <4507> said Thursday that it has applied with the health ministry for approval to manufacture and sell its COVID-19 vaccine, the first such vaccine developed by a Japanese drugmaker.
   Shionogi's vaccine is supposed to be used for the first, second and third vaccinations against COVID-19 for those aged 20 or older in the country.
   The vaccine is a recombinant protein-based type that is different from messenger RNA vaccines, including one developed by U.S. drug giant Pfizer Inc., that are widely used in Japan now.
   Shionogi is also developing a vaccine also targeting novel coronavirus variants including omicron and planning to accelerate efforts to put it to practical use.
   In December 2020, the company started a clinical trial for the COVID-19 vaccine for which it has applied for approval.

To read a full story, please click here to find out how to subscribe.

NATION

HEADLINES

POLITICS
PM Kishida Tops 2021 Income Rankings among Party Leaders, with Over 200 M. Yen
ECONOMY
Japan's Diet OKs Another Extra Govt Budget for Measures to Tackle Rising Prices
SPORTS
Golf: Kodaira, Kennedy in Tie to Lead Nippon Series JT Cup after Round 2
OTHER
Japan Seen Lowering Govt-Set Drug Prices as Market Prices 7% Lower Now

AFP-JIJI PRESS NEWS JOURNAL


Photos